Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

Chief Financial Officer

President

Chief Legal Officer

President and CSO

President & CSO

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from ser...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-02	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	President
2024-04-01	Premium	sold	Premium	Premium	Premium	CEO
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-03-31	Premium	acquired	Premium	Premium	Premium	President
2024-03-31	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-28	Premium	sold	Premium	Premium	Premium	CEO
2024-02-14	Premium	sold	Premium	Premium	Premium	-
2024-02-13	Premium	sold	Premium	Premium	Premium	-
2024-01-31	Premium	sold	Premium	Premium	Premium	CEO
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-12-22	Premium	sold	Premium	Premium	Premium	-
2023-11-20	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2023-11-20	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-10-30	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-10-20	Premium	acquired	Premium	Premium	Premium	President and CSO
2023-10-02	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-07-24	Premium	acquired	Premium	Premium	Premium	President and CSO
2023-07-24	Premium	sold	Premium	Premium	Premium	President and CSO
2023-07-21	Premium	sold	Premium	Premium	Premium	President and CSO

BEAM - Beam Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for BEAM